Investor profile

GrayBella Capital logo

GrayBella Capital

VC

GBIEESPTNLDEFRSEFIPLEELVLTHealthtechDeep TechAI/MLB2B SaaSFintechBio/Pharma

See how your deck fits this investor's thesis, stage, and ticket size.

Analyse your fit

Investment thesis

GrayBella Capital is a pan-European growth-stage venture capital firm investing in HealthTech and Deep Tech companies. In HealthTech, the firm targets advancements in diagnostics, biomarker discovery, MedTech, remote patient monitoring, and platform technologies for drug development. In Deep Tech, investments span material science, robotics, SaaS platforms, IoT, cloud computing, AI, machine learning, and nanotechnologies. The firm partners with purpose-driven founders developing globally disruptive technologies, invests €3–15M per company over the life of the investment, leads or co-leads rounds, and focuses on pan-European companies with a preference for B2B models and clear liquidity pathways.

Notable quotes

Omnio has secured a significant market position, that will allow it to be a critical player in the Banking as a Service market.

Richard Kivel · CBInsights / Finextra press release on Omnio funding round · 2021-03-24

Team

Richard Kivel

Managing Director

HealthtechDeep TechFintechEnterprise

Ruta Laukien

Managing Partner

HealthtechBio/PharmaDeep Tech

Juan Naranjo

Principal

HealthtechDeep Tech

Recent investments

CompanyRoundSizeDate
SensiusSeries A$17m2025-06-11
OmnioConvertible Note$33m2021-03-24
ATAI Life SciencesSeries B+
CN BioSeries B+
BC PlatformsGrowth

Frequent co-investors

VC firmDeals together
European Innovation Council (EIC)1
UCEA1
Europa1
UNIIQ1
Opentech1

Fit check

Is GrayBella Capital a match for your startup?

Upload your deck and get an instant AI-powered fit analysis — see exactly how your startup aligns with this investor's thesis, stage focus, and ticket size.

Analyse your fit